There are currently 269 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
Online Tai Chi Intervention to Promote Smoking Cessation Among Cancer Survivors
NCT05941858
Recruiting
This clinical trial evaluates an online Tai Chi intervention to promote smoking cessation among cancer survivors. Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. It is a gentle form of exercise that can be done while sitting or standing and does not involve any medications or medical procedures. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on hea... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/24/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Cancer
Register for Updates
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
NCT02090530
Recruiting
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Cancer
Register for Updates
Promoting Access, Resources and Treatment Through Novel and Equitable Solutions for Cancer Care
NCT06481774
Recruiting
The purpose of this research is to evaluate a novel, integrated approach to providing navigation services to improve cancer outcomes and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Cancer
Register for Updates
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
NCT06416007
Recruiting
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor, Locally Advanced Carcinoma
Register for Updates
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Urology Centers of Alabama, PC, Homewood, Alabama +375 locations
Conditions: Cancer
Register for Updates
Patient-Centered Assessment of Symptoms and Outcomes
NCT03952624
Recruiting
Background: The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different causes. Researchers think a therapy to treat one type of fatigue in one condition should be able to treat that type of fatigue in other conditions. Objective: To understand the types of fatigue. Eligibility: Adults 18 and older who have felt fatigue for more than a month, and non-fatigued adults Design: Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Register for Updates
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
Recruiting
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +4 locations
Conditions: Multiple Myeloma, Cancer
Register for Updates
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
NCT00026650
Recruiting
Background: * This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our patients, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. * It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PD... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer
Register for Updates
Connect for Cancer Prevention Study (Connect)
NCT04609072
Recruiting
Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk. Objective: To study and... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
05/09/2025
Locations: Kaiser Permanente Colorado, Denver, Colorado +9 locations
Conditions: Cancer, General Research Use
Register for Updates
Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT06056791
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California +7 locations
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Register for Updates
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
NCT05096923
Recruiting
Purpose: This study aims to create a registry of childhood, adolescent, and young adult patients with cancer (\<40 years-old at cancer diagnosis), entitled the 'UNC Childhood, Adolescent, and Young Adult Cancer Cohort' (UNC-CAYACC). This resource will serve to support cancer outcomes research among pediatric and young adult cancer patients with a primary focus on enrolling patients treated as adolescents or young adults (AYAs, 15-39 years). Procedures: As appropriate for age, participants will... Read More
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/07/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Pediatric Cancer, Cancer, Cancer Metastatic, Survivorship
Register for Updates
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT05588141
Recruiting
Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations. Eligibility: People aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 gene... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Brain Tumor, Cancer
Register for Updates